Literature DB >> 21770892

Evidence of SHIP2 Ser132 phosphorylation, its nuclear localization and stability.

William's Elong Edimo1, Rita Derua, Veerle Janssens, Takeshi Nakamura, Jean-Marie Vanderwinden, Etienne Waelkens, Christophe Erneux.   

Abstract

PtdIns(3,4,5)P3 and PtdIns(3,4)P2 are major signalling molecules in mammalian cell biology. PtdIns(3,4)P2 can be produced by PI3Ks [PI (phosphoinositide) 3-kinases], but also by PI 5-phosphatases including SHIP2 [SH2 (Src homology 2)-domain-containing inositol phosphatase 2]. Proteomic studies in human cells revealed that SHIP2 can be phosphorylated at more than 20 sites, but their individual function is unknown. In a model of PTEN (phosphatase and tensin homologue deleted on chromosome 10)-null astrocytoma cells, lowering SHIP2 expression leads to increased PtdIns(3,4,5)P3 levels and Akt phosphorylation. MS analysis identified SHIP2 phosphosites on Ser132, Thr1254 and Ser1258; phosphotyrosine-containing sites were undetectable. By immunostaining, total SHIP2 concentrated in the perinuclear area and in the nucleus, whereas SHIP2 phosphorylated on Ser132 was in the cytoplasm, the nucleus and nuclear speckles, depending on the cell cycle stage. SHIP2 phosphorylated on Ser132 demonstrated PtdIns(4,5)P2 phosphatase activity. Endogenous phospho-SHIP2 (Ser132) showed an overlap with PtdIns(4,5)P2 staining in nuclear speckles. SHIP2 S132A was less sensitive to C-terminal degradation and more resistant to calpain as compared with wild-type enzyme. We have identified nuclear lamin A/C as a novel SHIP2 interactor. We suggest that the function of SHIP2 is different at the plasma membrane where it recognizes PtdIns(3,4,5)P3, and in the nucleus where it may interact with PtdIns(4,5)P2, particularly in speckles.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21770892     DOI: 10.1042/BJ20110173

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  11 in total

Review 1.  The impact of phosphoinositide 5-phosphatases on phosphoinositides in cell function and human disease.

Authors:  Ana Raquel Ramos; Somadri Ghosh; Christophe Erneux
Journal:  J Lipid Res       Date:  2018-09-07       Impact factor: 5.922

Review 2.  Nuclear Lipids in the Nervous System: What they do in Health and Disease.

Authors:  Mercedes Garcia-Gil; Elisabetta Albi
Journal:  Neurochem Res       Date:  2016-10-20       Impact factor: 3.996

Review 3.  When PIP2 Meets p53: Nuclear Phosphoinositide Signaling in the DNA Damage Response.

Authors:  Yu-Hsiu Wang; Michael P Sheetz
Journal:  Front Cell Dev Biol       Date:  2022-05-13

Review 4.  Phosphoinositides: tiny lipids with giant impact on cell regulation.

Authors:  Tamas Balla
Journal:  Physiol Rev       Date:  2013-07       Impact factor: 37.312

Review 5.  The nuclear phosphoinositide response to stress.

Authors:  Mo Chen; Tianmu Wen; Hudson T Horn; Vishwanatha K Chandrahas; Narendra Thapa; Suyong Choi; Vincent L Cryns; Richard A Anderson
Journal:  Cell Cycle       Date:  2020-01-05       Impact factor: 4.534

6.  Tools for visualization of phosphoinositides in the cell nucleus.

Authors:  Ilona Kalasova; Veronika Fáberová; Alžběta Kalendová; Sukriye Yildirim; Lívia Uličná; Tomáš Venit; Pavel Hozák
Journal:  Histochem Cell Biol       Date:  2016-02-04       Impact factor: 4.304

7.  A synthetic polyphosphoinositide headgroup surrogate in complex with SHIP2 provides a rationale for drug discovery.

Authors:  Stephen J Mills; Camilla Persson; Gyles Cozier; Mark P Thomas; Lionel Trésaugues; Christophe Erneux; Andrew M Riley; Pär Nordlund; Barry V L Potter
Journal:  ACS Chem Biol       Date:  2012-02-27       Impact factor: 5.100

Review 8.  Nuclear PI3K signaling in cell growth and tumorigenesis.

Authors:  William J Davis; Peter Z Lehmann; Weimin Li
Journal:  Front Cell Dev Biol       Date:  2015-04-13

9.  Super-Resolution Localisation of Nuclear PI(4)P and Identification of Its Interacting Proteome.

Authors:  Veronika Fáberová; Ilona Kalasová; Alžběta Krausová; Pavel Hozák
Journal:  Cells       Date:  2020-05-11       Impact factor: 6.600

Review 10.  Targeting SHIP1 and SHIP2 in Cancer.

Authors:  Chiara Pedicone; Shea T Meyer; John D Chisholm; William G Kerr
Journal:  Cancers (Basel)       Date:  2021-02-20       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.